Inhibikase reports Q3 2026 results and outlines Phase 3 PAH trial progress.
Inhibikase advanced its Phase 3 IMPROVE-PAH trial with 79 sites activated globally and secured $50 million in July 2026. This cash injection strengthens its financial position to finance the pivotal study for PAH.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed